We are pleased to announce that our application to the “Strengthening Program for Pharmaceutical Startup Ecosystem” administered by the Japan Agency for Medical Research and Development (AMED) for the development of our lead compound, SNT‑001, for treatment of peripheral neuropathy and neuropathic pain, has been approved.

https://www.amed.go.jp/koubo/03008/01/C_00002.html

This achievement has been made possible through the dedicated efforts and generous support of all parties involved, including Toray Industries, Inc., the originator of this compound. We would like to express our deepest appreciation for their invaluable contributions.
In alignment with the objectives of this program, we will continue to advance the development with renewed commitment and discipline, striving to achieve overall program success. We sincerely appreciate your continued guidance and support.